CSIMarket
 

Fate Therapeutics Inc   (NASDAQ: FATE)
Other Ticker:  
 

Fate Therapeutics Inc 's

Competitiveness



 
 

FATE Sales vs. its Competitors Q1 2025



Comparing the current results to its competitors, Fate Therapeutics Inc reported Revenue decrease in the 1 quarter 2025 year on year by -15.38 %, slower than the combined decrease of the FATE's competitors by -30.17 %, recorded in the same quarter.

List of FATE Competitors





Revenue Growth Comparisons




Net Income Comparison


Fate Therapeutics Inc recorded a net loss, despite income increase by most of its competitors of 0 %

<<  FATE Stock Performance Comparisons



  

Overall company Market Share Q1 2025

despite revenue deterioration, Fate Therapeutics Inc increased its market share in this segment.

company increased its market share in this segment to approximately 0.01 %.


<<  More on FATE Market Share.
 
*Market share is calculated based on total revenue.

  News about Fate Therapeutics Inc Contracts

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidat...

November 8, 2024
Cutting-Edge CAR T-Cell Therapy: Fate Therapeutics? Breakthrough Data and Stellar Financial Performance Set to Revolutionize Cancer TreatmentIn an era where advancements in immunotherapy are reshaping oncological treatment paradigms, Fate Therapeutics, Inc. has emerged as a frontrunner with the presentation of its preclinical data for its innovative FT836 product candidate. Highlighted at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), FT836 represents a cutting-edge leap in the realm of CAR T-cell therapies. This multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived CAR T-cell product targets specific proteins expressed on cancer cells that are both a product of ce...

Fate Therapeutics Pioneers Off-the-Shelf CAR T-Cell Therapies, Showing Promise in Treating Lupus and HER2-expressing Advanced Solid Tumors

May 9, 2024
Fate Therapeutics, a leading biopharmaceutical company focused on the development of off-the-shelf cell therapies, recently announced significant advancements in their groundbreaking CAR T-cell programs for the treatment of autoimmune disorders and advanced solid tumors. The company has successfully treated the first Lupus patient in their Phase 1 Autoimmunity Study using the FT819 CAR T-cell program, while also initiating a Phase 1 Clinical Trial for the HER2-expressing advanced solid tumors treatment with FT825/ONO-8250 iPSC-derived CAR T-cell product candidate.In the Phase 1 Autoimmunity Study, Fate Therapeutics demonstrated the efficacy of their off-the-shelf FT819 CAR T-cell program in the treatment of ...

Revolutionizing Cancer Treatment: Fate Therapeutics Leads the Charge with Phase 1 Trial of iPSC-Derived CAR T-cell Therapy

January 8, 2024
San Diego-based biopharmaceutical company Fate Therapeutics, in conjunction with Ono Pharmaceutical Co., recently announced the initiation of a groundbreaking Phase 1 Clinical Trial for cellular immunotherapy FT825/ONO-8250 in patients battling HER2-expressing advanced solid tumors. Encompassing a novel HER2-targeted antigen-binding domain, this innovative product candidate originates from induced pluripotent stem cells (iPSCs).Fate Therapeutics, notable for its transformative work in cell-based cancer immunotherapy, is incorporating an unprecedented seven synthetic controls of cell function into FT825/ONO-8250 in its pursuit of pioneering novel treatments. HER2 (human epidermal growth factor receptor 2) is ...





Publicly Traded Peers of Fate Therapeutics Inc




Adicet Bio Inc
Share Performance



-9.14%
Over The Past 5 Days



Adicet Bio Inc
Profile

Adicet Bio Inc's business model involves the development and commercialization of cell therapy medications for various diseases.

More about Adicet Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 59.470 mill. $ - mill. $ -117.320 mill.


Adaptimmune Therapeutics Plc
Share Performance



-53.82%
This Quarter



Adaptimmune Therapeutics Plc
Profile

Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.

More about Adaptimmune Therapeutics Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 418.079 mill. $ 179.889 mill. $ -69.895 mill.


Vincerx Pharma Inc
Share Performance



-95.60%
This Quarter



Vincerx Pharma Inc
Profile

Vincerx Pharma Inc's business model is focused on developing and commercializing novel small molecule drugs for the treatment of cancer. They aim to leverage their scientific expertise and collaborations to identify and advance promising drug candidates, ultimately providing innovative therapies to patients in need.

More about Vincerx Pharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.172 mill. $ - mill. $ -22.645 mill.


Verastem Inc
Share Performance



+9.18%
30 Days



Verastem Inc
Profile

Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.

More about Verastem Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 412.257 mill. $ - mill. $ -148.877 mill.


Bellicum Pharmaceuticals Inc
Share Performance



-65.67%
This Quarter



Bellicum Pharmaceuticals Inc
Profile

Bellicum Pharmaceuticals Inc's business model is focused on the development and commercialization of innovative cellular immunotherapies for the treatment of cancers and other serious diseases.

More about Bellicum Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.312 mill. $ 1.480 mill. $ 2.593 mill.


Oncosec Medical Incorporated
Share Performance



-85.64%
This Quarter



Oncosec Medical Incorporated
Profile

Oncosec Medical Incorporated's business model revolves around developing and commercializing innovative immunotherapies for the treatment of various cancers.

More about Oncosec Medical Incorporated's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.717 mill. $ - mill. $ -29.386 mill.


Oncorus Inc
Share Performance



-54.69%
This Year



Oncorus Inc
Profile

Oncorus Inc is a biotechnology company that specializes in developing next-generation viral immunotherapies to treat various types of cancers. Their business model revolves around leveraging the power of oncolytic viruses, which selectively target and destroy cancer cells while stimulating an immune response against the tumor. Oncorus focuses on rigorous research, clinical development, and potential partnerships to advance their innovative therapies towards commercialization and widespread patient access.

More about Oncorus Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.288 mill. $ - mill. $ -90.541 mill.


Athersys Inc
Share Performance



-98.76%
One Year



Athersys Inc
Profile

Athersys Inc's business model revolves around the development and commercialization of novel cellular therapeutics.

More about Athersys Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.339 mill. $ - mill. $ -83.371 mill.


Tcr2 Therapeutics Inc
Share Performance



+58.00%
This Year



Tcr2 Therapeutics Inc
Profile

TCR2 Therapeutics Inc is a biotechnology company that focuses on the development of innovative immunotherapies for cancer treatment. Their business model entails leveraging their proprietary T-cell receptor (TCR) Fusion Construct T cells platform to create therapies that effectively target and eliminate cancer cells.

More about Tcr2 Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 61.969 mill. $ - mill. $ -163.099 mill.


Tectonic Therapeutic Inc
Share Performance



+6.55%
30 Days



Tectonic Therapeutic Inc
Profile



More about Tectonic Therapeutic Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 369.748 mill. $ - mill. $ -67.080 mill.


Pmv Pharmaceuticals Inc
Share Performance



-41.17%
This Year



Pmv Pharmaceuticals Inc
Profile

Pmv Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing precision therapies for cancer patients. They employ a collaborative business model that combines deep scientific expertise, strategic partnerships, and advanced technology to identify and target specific genetic alterations in cancer cells. By leveraging these insights, Pmv Pharmaceuticals aims to create innovative treatments that can improve patient outcomes and address unmet medical needs in oncology.

More about Pmv Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 46.762 mill. $ - mill. $ -60.875 mill.


Celularity Inc
Share Performance



+58.78%
30 Days



Celularity Inc
Profile

Celularity is a biotechnology company that focuses on developing and delivering transformative cellular therapies for various diseases. Their business model encompasses acquiring and licensing cellular assets, conducting research and development to advance these therapies, and forming strategic partnerships with healthcare organizations and research institutions to commercialize and distribute their innovative products. Through this model, Celularity aims to address unmet medical needs and provide novel therapies to improve patient outcomes.

More about Celularity Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 51.644 mill. $ 48.200 mill. $ -35.052 mill.


Geron Corp
Share Performance



-17.82%
This Quarter



Geron Corp
Profile

Geron Corp is a biopharmaceutical company that focuses on the discovery and development of therapeutic products for the treatment of cancer and chronic degenerative diseases. Their business model is based on researching and identifying innovative drug candidates, conducting preclinical and clinical trials to evaluate their safety and efficacy, and ultimately partnering with larger pharmaceutical companies for late-stage clinical development and commercialization. Geron Corp aims to leverage their scientific expertise and strategic collaborations to bring novel therapies to market and improve patient outcomes.

More about Geron Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 952.245 mill. $ 115.794 mill. $ -139.017 mill.


Atreca inc
Share Performance



-31.14%
This Year



Atreca inc
Profile

Atreca Inc operates on a unique business model focused on developing novel therapeutics by leveraging its proprietary Immune Repertoire Capture (IRC) technology to analyze and identify antibodies present in patients with specific diseases, ultimately enabling the development of targeted therapies.

More about Atreca inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.542 mill. $ - mill. $ -97.756 mill.


Cabaletta Bio Inc
Share Performance



-1.06%
This Quarter



Cabaletta Bio Inc
Profile

Cabaletta Bio Inc's business model revolves around developing and commercializing genetically engineered T cell therapies for the treatment of autoimmune diseases. They aim to utilize their proprietary technology platform to engineer Chimeric AutoAntibody Receptor (CAAR) T cells, which are designed to selectively target and eliminate disease-causing B cells. By focusing on autoimmune diseases with high unmet medical needs, Cabaletta Bio Inc aims to provide effective and personalized therapeutic solutions to patients.

More about Cabaletta Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 94.667 mill. $ - mill. $ -126.760 mill.


Bluebird Bio Inc
Share Performance



-42.69%
This Year



Bluebird Bio Inc
Profile

Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.

More about Bluebird Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 48.560 mill. $ 103.946 mill. $ 139.438 mill.


Bristol myers Squibb Company
Share Performance



-16.48%
This Year



Bristol myers Squibb Company
Profile

Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.

More about Bristol myers Squibb Company's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 97,073.400 mill. $ 47,636.000 mill. $ 5,437.000 mill.


Allogene Therapeutics Inc
Share Performance



-25.97%
30 Days



Allogene Therapeutics Inc
Profile

Allogene Therapeutics Inc has a business model that focuses on developing and commercializing innovative allogeneic CAR T cell therapies for the treatment of cancer.

More about Allogene Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 245.509 mill. $ - mill. $ -252.323 mill.


Cell Source Inc
Share Performance



0.00%
30 Days



Cell Source Inc
Profile

Cell Source Inc is a biotechnology company that specializes in the development and commercialization of innovative treatments for diseases. Their business model focuses on leveraging advanced cell therapy technologies to create personalized and regenerative therapies for patients. By partnering with research institutions and healthcare organizations, Cell Source aims to bring their cutting-edge solutions to the market, ultimately improving health outcomes and patient quality of life.

More about Cell Source Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11.298 mill. $ - mill. $ -5.317 mill.


Maia Biotechnology Inc
Share Performance



-58.54%
One Year



Maia Biotechnology Inc
Profile

Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.

More about Maia Biotechnology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 50.408 mill. $ - mill. $ -19.704 mill.


Carisma Therapeutics Inc
Share Performance



-55.56%
This Year



Carisma Therapeutics Inc
Profile

Carisma Therapeutics Inc's business model focuses on developing novel CAR-Macrophage cell therapies to treat solid tumors. They aim to leverage their proprietary technology platform to engineer immune cells that can effectively target and destroy cancer cells, while also optimizing the manufacturing process for scalability and cost-effectiveness.

More about Carisma Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 8.170 mill. $ 19.964 mill. $ -41.053 mill.


Enlivex Therapeutics Ltd
Share Performance



-23.39%
This Year



Enlivex Therapeutics Ltd
Profile

Enlivex Therapeutics Ltd's business model focuses on developing and commercializing novel immune system therapies.

More about Enlivex Therapeutics Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 17.646 mill. $ - mill. $ -29.068 mill.


Marker Therapeutics inc
Share Performance



-24.83%
This Quarter



Marker Therapeutics inc
Profile

Marker Therapeutics Inc is a biotechnology company that aims to develop and commercialize novel T cell immunotherapies for the treatment of cancer. Their business model focuses on leveraging their expertise in cellular engineering to develop proprietary technologies and therapies that can be licensed or partnered with other organizations for further development and commercialization.

More about Marker Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 10.337 mill. $ 6.591 mill. $ -10.731 mill.


Merus N v
Share Performance



-1.60%
Over The Past 5 Days



Merus N v
Profile

Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.

More about Merus N v 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,744.894 mill. $ 54.732 mill. $ -277.344 mill.


Autolus Therapeutics Plc
Share Performance



+25.95%
30 Days



Autolus Therapeutics Plc
Profile

Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.

More about Autolus Therapeutics Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 439.109 mill. $ 9.011 mill. $ -238.133 mill.


Surface Oncology Inc
Share Performance



0.00%
Over The Past 5 Days



Surface Oncology Inc
Profile

Surface Oncology Inc is a biotechnology company focused on developing innovative immunotherapies to treat cancer. They employ a research-driven approach to identify and target novel immune checkpoints and design therapeutic antibodies to activate the immune system against tumors. Their business model revolves around conducting preclinical and clinical research, collaborating with strategic partners, and licensing or commercializing their products to bring new treatment options to patients.

More about Surface Oncology Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 64.968 mill. $ - mill. $ -92.505 mill.


Agenus Inc
Share Performance



-20.32%
Over The Past 5 Days



Agenus Inc
Profile

Agenus Inc is a biotechnology company that primarily focuses on the discovery and development of immune-based therapies for cancer treatment. Their business model revolves around leveraging their proprietary technologies and capabilities to develop and commercialize therapeutic antibodies and vaccines. Agenus Inc also collaborates with other pharmaceutical companies through licensing agreements and partnerships to further advance their product pipeline.

More about Agenus Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 73.896 mill. $ 99.524 mill. $ -195.187 mill.


Poseida Therapeutics Inc
Share Performance



+1.06%
This Year



Poseida Therapeutics Inc
Profile

Poseida Therapeutics Inc's business model revolves around developing and commercializing gene therapies for a wide range of diseases and conditions.

More about Poseida Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 933.089 mill. $ 150.858 mill. $ -60.759 mill.


Gilead Sciences Inc
Share Performance



+72.94%
One Year



Gilead Sciences Inc
Profile

Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.

More about Gilead Sciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 139,522.506 mill. $ 28,735.000 mill. $ 5,965.000 mill.


Moderna Inc
Share Performance



-82.26%
One Year



Moderna Inc
Profile

Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.

More about Moderna Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 10,375.680 mill. $ 3,177.000 mill. $ -3,357.000 mill.


Amgen Inc
Share Performance



-7.86%
This Quarter



Amgen Inc
Profile

Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.

More about Amgen Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ 5,933.000 mill.


Lenz Therapeutics Inc
Share Performance



+1.48%
This Year



Lenz Therapeutics Inc
Profile



More about Lenz Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 790.274 mill. $ - mill. $ -47.740 mill.


Zeo Scientifix Inc
Share Performance



-61.04%
This Year



Zeo Scientifix Inc
Profile

Organicell Regenerative Medicine Inc's business model focuses on developing and commercializing regenerative therapies derived from perinatal tissues, such as placental tissues and umbilical cord blood.

More about Zeo Scientifix Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.381 mill. $ 4.556 mill. $ -4.908 mill.


Peak Bio Inc
Share Performance



0.00%
30 Days



Peak Bio Inc
Profile

Peak Bio Inc is a biotechnology company specializing in the development and commercialization of innovative medical products. Their business model focuses on conducting extensive research and development to create cutting-edge biopharmaceuticals. These products are then marketed and distributed to healthcare providers and patients, aiming to improve patient outcomes and contribute to advancements in the healthcare industry.

More about Peak Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.422 mill. $ - mill. $ -3.324 mill.


Tracon Pharmaceuticals Inc
Share Performance



-29.07%
30 Days



Tracon Pharmaceuticals Inc
Profile

Tracon Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing targeted therapies for cancer and ocular diseases. They primarily collaborate with strategic partners to advance their drug candidates through clinical trials and potentially secure regulatory approval.

More about Tracon Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.097 mill. $ 3.200 mill. $ 5.195 mill.


Brainstorm Cell Therapeutics inc
Share Performance



-86.64%
One Year



Brainstorm Cell Therapeutics inc
Profile

Brainstorm Cell Therapeutics Inc's business model is centered around developing and commercializing innovative adult stem cell therapies for neurodegenerative diseases.

More about Brainstorm Cell Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6.723 mill. $ - mill. $ -11.086 mill.


Gamida Cell Ltd
Share Performance



-90.31%
This Quarter



Gamida Cell Ltd
Profile

Gamida Cell Ltd's business model is focused on developing and bringing innovative cell therapies to market for the treatment of various diseases, with a particular emphasis on hematological malignancies and serious blood disorders.

More about Gamida Cell Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6.108 mill. $ 1.563 mill. $ 21.465 mill.


Avalon Globocare Corp
Share Performance



-14.30%
One Year



Avalon Globocare Corp
Profile

Avalon Globocare Corp's business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.

More about Avalon Globocare Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 5.962 mill. $ 1.369 mill. $ -9.018 mill.


Atara Biotherapeutics Inc
Share Performance



+9.70%
Over The Past 5 Days



Atara Biotherapeutics Inc
Profile

Atara Biotherapeutics Inc is a biotechnology company that focuses on developing therapies for patients with serious medical conditions. They utilize a personalized medicine approach to create off-the-shelf, allogeneic T-cell immunotherapies. By leveraging their expertise in T-cell immunotherapy and genetic engineering, they aim to provide innovative treatments with the potential for broad patient reach.

More about Atara Biotherapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 84.638 mill. $ 303.057 mill. $ -15.641 mill.


Senti Biosciences Inc
Share Performance



-1.56%
Over The Past 5 Days



Senti Biosciences Inc
Profile

Senti Biosciences Inc is a biotechnology company that develops and commercializes novel therapeutics using synthetic biology and gene editing technology.

More about Senti Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 31.541 mill. $ - mill. $ -54.791 mill.


Biocardia Inc
Share Performance



-30.82%
30 Days



Biocardia Inc
Profile

Biocardia Inc's business model involves developing and commercializing innovative medical therapies and devices to treat cardiovascular diseases.

More about Biocardia Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9.781 mill. $ - mill. $ -8.391 mill.


Kiromic Biopharma Inc
Share Performance



-85.18%
Over The Past 5 Days



Kiromic Biopharma Inc
Profile

Kiromic Biopharma Inc is a biotechnology company that focuses on developing targeted immunotherapies for the treatment of cancer. Their business model revolves around utilizing their proprietary technology platforms to identify tumor-specific antigens and develop personalized therapies to effectively target and eliminate cancer cells.

More about Kiromic Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.004 mill. $ - mill. $ -26.898 mill.


Coeptis Therapeutics Holdings Inc
Share Performance



+53.30%
This Year



Coeptis Therapeutics Holdings Inc
Profile

Coeptis Therapeutics Holdings Inc. is a pharmaceutical company that focuses on the development and commercialization of innovative therapies. Their business model involves researching, formulating, and manufacturing drugs to address unmet medical needs in various therapeutic areas. They aim to bring these treatments to market to improve patient outcomes and generate revenue through sales and licensing agreements.

More about Coeptis Therapeutics Holdings Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 27.842 mill. $ 0.063 mill. $ -9.870 mill.


Organovo Holdings Inc
Share Performance



-52.43%
This Quarter



Organovo Holdings Inc
Profile

Organovo Holdings Inc is a biotechnology company that specializes in creating functional 3D human tissue models for medical research and therapeutic purposes. They use a combination of 3D bioprinting and other innovative technologies to produce highly precise and realistic tissue constructs. These models are utilized by pharmaceutical companies to accelerate the drug discovery process and potentially reduce the need for animal testing.

More about Organovo Holdings Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.070 mill. $ 0.093 mill. $ 1.270 mill.


Compass Therapeutics Inc
Share Performance



0.00%
Over The Past 5 Days



Compass Therapeutics Inc
Profile

Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.

More about Compass Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 290.296 mill. $ - mill. $ -55.221 mill.


Gritstone Bio Inc
Share Performance



-98.52%
This Year



Gritstone Bio Inc
Profile

Gritstone Bio Inc is a biotechnology company that focuses on developing personalized cancer immunotherapies. Their business model revolves around utilizing their proprietary genomics platform to identify patient-specific tumor targets and developing therapies that stimulate the immune system to recognize and attack cancer cells.

More about Gritstone Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 4.614 mill. $ 14.609 mill. $ -200.997 mill.


Turnstone Biologics Corp
Share Performance



-7.92%
This Quarter



Turnstone Biologics Corp
Profile

Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.

More about Turnstone Biologics Corp 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 7.992 mill. $ - mill. $ -63.014 mill.


Humacyte Inc
Share Performance



-45.37%
This Year



Humacyte Inc
Profile

Humacyte Inc is a biotechnology company that focuses on creating bioengineered human tissue constructs for numerous medical applications. Their business model revolves around developing and commercializing their proprietary Humacyl platform, which uses a patient's own cells to create acellular scaffolds that mimic human tissue. These tissue constructs can be used for various purposes such as vascular replacements, functional tissues, and potential regenerative medicine therapies.

More about Humacyte Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 372.879 mill. $ 19.302 mill. $ -77.666 mill.


Nkgen Biotech Inc
Share Performance



+96.29%
30 Days



Nkgen Biotech Inc
Profile

Nkgen Biotech Inc is a biotechnology company that focuses on developing and commercializing innovative cell therapies for the treatment of various diseases. Their business model involves conducting extensive research to identify and isolate specific cells capable of addressing medical conditions, followed by developing manufacturing processes to produce these cells in large quantities. They aim to partner with healthcare providers and pharmaceutical companies to ensure the effective distribution and delivery of their therapies to patients in need.

More about Nkgen Biotech Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11.366 mill. $ - mill. $ -72.687 mill.


Century Therapeutics inc
Share Performance



-46.15%
This Year



Century Therapeutics inc
Profile

Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.

More about Century Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 44.023 mill. $ 6.589 mill. $ -126.566 mill.


Armata Pharmaceuticals Inc
Share Performance



+35.94%
30 Days



Armata Pharmaceuticals Inc
Profile

Armata Pharmaceuticals Inc operates on a research and development business model focused on discovering and developing bacteriophage-based therapies to combat antibiotic-resistant infections. They utilize their proprietary phage technology platform to create novel pharmaceutical products targeting various bacterial diseases.

More about Armata Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 123.716 mill. $ - mill. $ -0.426 mill.


Molecular Partners Ag
Share Performance



-11.45%
Over The Past 5 Days



Molecular Partners Ag
Profile

Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.

More about Molecular Partners Ag's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 117.237 mill. $ 7.038 mill. $ -61.984 mill.


Sutro Biopharma Inc
Share Performance



-78.45%
One Year



Sutro Biopharma Inc
Profile

Sutro Biopharma Inc has a business model focused on developing and commercializing innovative antibody-based therapeutics.

More about Sutro Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 76.100 mill. $ 66.434 mill. $ -245.216 mill.


Genenta Science S p a
Share Performance



-1.99%
This Year



Genenta Science S p a
Profile

Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.

More about Genenta Science S p a 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -9.982 mill.


Tscan Therapeutics Inc
Share Performance



-8.81%
30 Days



Tscan Therapeutics Inc
Profile

Tscan Therapeutics Inc is a biotechnology company that focuses on developing and commercializing T cell receptor therapies for cancer patients. Their business model revolves around leveraging their T cell platform to develop innovative treatments and secure partnerships with other pharmaceutical companies for clinical development and commercialization.

More about Tscan Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 188.034 mill. $ 4.421 mill. $ -131.484 mill.


Meiragtx Holdings Plc
Share Performance



-24.96%
30 Days



Meiragtx Holdings Plc
Profile

MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.

More about Meiragtx Holdings Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 420.452 mill. $ 34.508 mill. $ -167.330 mill.


Instil Bio Inc
Share Performance



+33.75%
This Quarter



Instil Bio Inc
Profile

Instil Bio Inc operates with a business model focusing on developing and commercializing innovative cell therapy products for the treatment of cancer. They aim to leverage advanced technologies and strategic partnerships to advance their pipeline and bring novel therapies to market.

More about Instil Bio Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 174.749 mill. $ 6.509 mill. $ -78.033 mill.


Iovance Biotherapeutics inc
Share Performance



0.00%
Over The Past 5 Days



Iovance Biotherapeutics inc
Profile

Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.

More about Iovance Biotherapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 565.019 mill. $ 212.679 mill. $ -375.364 mill.


Replimune Group Inc
Share Performance



-36.33%
This Quarter



Replimune Group Inc
Profile

Replimune Group Inc has a business model centered around the development of oncolytic immunotherapies.

More about Replimune Group Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 679.060 mill. $ - mill. $ -247.297 mill.


Aura Biosciences Inc
Share Performance



-20.00%
This Quarter



Aura Biosciences Inc
Profile

Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.

More about Aura Biosciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 298.008 mill. $ - mill. $ -86.919 mill.


Ambrx Biopharma Inc
Share Performance



+0.21%
Over The Past 5 Days



Ambrx Biopharma Inc
Profile

Ambrx Biopharma Inc's business model can be described as a biopharmaceutical company that focuses on developing protein therapeutics through the use of its proprietary technology called ReCODE?.

More about Ambrx Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,743.012 mill. $ 8.602 mill. $ -134.113 mill.


Lexeo Therapeutics Inc
Share Performance



-23.25%
30 Days



Lexeo Therapeutics Inc
Profile

Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.

More about Lexeo Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 90.732 mill. $ - mill. $ -109.307 mill.


Revolution Medicines Inc
Share Performance



-14.25%
This Year



Revolution Medicines Inc
Profile

Revolution Medicines Inc operates as a biopharmaceutical company that focuses on discovering and developing new drugs to target cancers and other diseases caused by defects in cellular signaling. Their business model involves leveraging their expertise in precision oncology and molecular biology to identify novel drug candidates and advance them through preclinical and clinical development stages.

More about Revolution Medicines Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6,324.444 mill. $ - mill. $ -600.093 mill.


Immunocore Holdings Plc
Share Performance



+3.35%
30 Days



Immunocore Holdings Plc
Profile



More about Immunocore Holdings Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,635.899 mill. $ 333.581 mill. $ -21.628 mill.


Immunitybio inc
Share Performance



+3.56%
Over The Past 5 Days



Immunitybio inc
Profile

Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.

More about Immunitybio inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,235.284 mill. $ 31.222 mill. $ -409.181 mill.


Immix Biopharma Inc
Share Performance



-19.09%
Over The Past 5 Days



Immix Biopharma Inc
Profile

ImmIx Biopharma Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer. Their business model involves conducting extensive research and development to discover and optimize drug candidates, followed by preclinical and clinical testing to assess their safety and effectiveness. They aim to collaborate with pharmaceutical companies or seek licensing agreements to further develop and commercialize their biopharmaceutical products.

More about Immix Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 55.455 mill. $ - mill. $ -21.698 mill.


Neximmune Inc
Share Performance



0.00%
This Quarter



Neximmune Inc
Profile

Neximmune Inc is a biotechnology company that focuses on developing personalized immunotherapies to treat various cancers and autoimmune diseases.

More about Neximmune Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.000 mill. $ - mill. $ -20.617 mill.


Phoenix Biotech Acquisition Corp
Share Performance



-5.98%
This Year



Phoenix Biotech Acquisition Corp
Profile

Phoenix Biotech Acquisition Corp is a company that focuses on acquiring and investing in biotech businesses.

More about Phoenix Biotech Acquisition Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.061 mill. $ - mill. $ -7.290 mill.




Sources: Fate Therapeutics Inc and all companies mentioned above in this report


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com